Abstract
The relationship between SARS-CoV-2 viral load and infectiousness is not known. Using data from a prospective cohort of index cases and high-risk contact, we reconstructed by modelling the viral load at the time of contact and the probability of infection. The effect of viral load was particularly large in household contacts, with a transmission probability that increased to as much as 37% when the viral load was greater than 10 log10 copies per mL. The transmission probability peaked at symptom onset in most individuals, with a median probability of transmission of 15%, that hindered large individual variations (IQR: [8, 37]). The model also projects the effects of variants on disease transmission. Based on the current knowledge that viral load is increased by 2 to 4-fold on average, we estimate that infection with B1.1.7 virus could lead to an increase in the probability of transmission by 8 to 17%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study has received financialsupport from the National Research Agency (ANR) through the ANR-Flashcall for COVID-19 (Grant ANR-20-COVI-0018) and the Bill and Melinda GatesFoundation under Grant Agreement INV-017335. The original trial was funded by a crowdfunding campaign YoMeCorono (https://www.yomecorono.com/), and Generalitat de Catalunyawith support for laboratory equipment fromFoundation Dormeur. We thank Samuel Alizon, Xavier Duvaland Xavier de Lamballerie for helpful discussions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this study originate from an original clinical study. Details on the study can be found in : Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. The trial protocol and subsequent amendments were approved by the institutional review board at Hospital Germans Trias i Pujol and the Spanish Agency of Medicines and Medical Devices. All the participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset used for this study is provided.
